Effective prevention of blood clots in critically ill patients

Not Applicable

Completed

• Conditions: Venous thromboembolism; Circulatory System; Other venous embolism and thrombosis

• Registration Number: ISRCTN03037804
• Lead Sponsor: Odense University Hospital (Denmark)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2009-03-31
• Study Start: 2010-02-22
• Last Update Posted: 27 May 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Consecutive patients admitted to the ICU
2. Aged over 18 years, either sex
3. Minimum stay of greater than 24 hours

Exclusion Criteria

1. Patients weighing less than 50 kg or greater than 90 kg
2. Bleeding diathesis
3. In need of an operation within the timeframe of the study
4. Pregnant
5. Requiring continuous veno-venous haemofiltration

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Peak anti-factor Xa levels (peak = 4 hours post-enoxaparin administration). Levels of anti-factor Xa activity were determined using a validated chromogenic assay kit (COAMATIC Heparin, Chromogenix, Instrumentation Laboratory Company, Lexington, USA) with the substrate S-2732, and the apparatus (STA-R Evolution, Diagnostica Stago, Asnieres, France).

Secondary Outcome Measures

Name	Time	Method
<br> 1. Antithrombin (AT)<br> 2. Prothrombin time (PT)<br> 3. Activated partial thromboplastin time (aPTT)<br> 4. Thrombin-antithrombin complexes (TAT), determined using an enzyme-immunoassay (Enzygnost&acirc; TAT micro, Siemens, Marburg, Germany)<br> 5. Fibrinogen<br> 6. Platelets<br> 7. D-dimer<br><br> Measured immediately before, and at 4, 12, and 24 hours after the administration of enoxaparin.<br>